Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 2Diagnosis: Pediatric SarcomaNCT ID: NCT00592592
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 04-188
The main purpose of this study is to see if using proton beam radiation therapy instead of photon beam radiation therapy can reduce side effects from radiation treatment for rhabdomyosarcoma. Photon beam radiation is the standard type of radiation for treating most rhabdomyosarcoma and many other types of cancer. Photon beam radiation enters the body and passes through healthy tissue, encounters the tumor, then leaves the body through healthy tissue. A beam of proton radiation enters the body and passes through healthy tissue, encounters tumor, but then stops. This means that less healthy tissue is affected by proton beam radiation than by photon beam radiation.
Conducting Institutions: Dana-Farber Cancer Institute, Massachusetts General Hospital, Children's Hospital Boston, Brigham and Women's Hospital
Overall PI: Torunn Yock, MD,
Massachusetts General Hospital
Site-responsible Investigators: Karen Marcus, MD,
Brigham and Women's Hospital
Contacts: Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100Dana-Farber Cancer Institute:
Childrens Hospital Pediatric Clinical Translation Investigation Program CTIP,